[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 12, 2009

Is What Is Good for the Gander Really Good for the Goose?

Author Affiliations

Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009

Arch Intern Med. 2009;169(16):1460-1461. doi:10.1001/archinternmed.2009.261

The use of implantable cardioverter- defibrillators (ICDs) has grown rapidly in the last decade. Originally reserved for only the highest-risk patients such as survivors of sudden cardiac death (SCD), use of ICDs has expanded to include primary prevention following the publication of 2 randomized clinical trials establishing their efficacy.1,2 Since then, the great challenge in ICD use has been to identify those at greatest risk for SCD—that is, the population who would benefit the most from implantation. Cardiologists have used various criteria, such as the width of QRS and T-wave alternans, for risk stratification. Meanwhile, the use of ICDs has expanded even beyond those with heart failure to include younger patients with such conditions as arrhythmogenic right ventricular dysplasia, long QT syndrome, and hypertrophic cardiomyopathy.3